Skip to main content

Table 3 Dose reduction levels

From: First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: a phase II study protocol OGSG 1602

Level

Panitumumab

0

6 mg/Kg

-1

4.8 mg/Kg

-2

3.6 mg/Kg

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us